Affiliation:
1. Xinjiang Medical University
2. First Affiliated Hospital of Xinjiang Medical University
Abstract
Abstract
Objective
To screen for miRNAs differentially expressed in prostate cancer and prostate hyperplasia tissues and to validate their association with prostate cancer.
Methods
Patients diagnosed by pathology in the Department of Urology of the First Affiliated Hospital of Xinjiang Medical University from October 2021 to June 2022 were selected and their general clinical information, blood samples and prostate tissue samples were collected; miRNA microarray technology was performed to obtain differentially expressed miRNAs in prostate cancer and hyperplasia tissues, and miRNAs to be studied were screened by microarray results and review of relevant literature; detection of miRNAs expression in the patients' blood and prostate tissue samples was measured; the miRNA-222-mimics were transfected into PC3 cells, and cell biology experiments such as CCK8, scratch, Transwell and flow cytometry were performed to detect the effects of overexpressed miRNA-222 on the growth and proliferation, invasive ability, apoptotic ability and metastatic ability of prostate cancer cells.
Results
The results of miRNA microarray showed that there were many differentially expressed miRNAs in prostate cancer and hyperplasia tissues, and four miRNAs, miRNA-144, miRNA-222, miRNA-1248 and miRNA-3651 were finally selected as the subjects by reviewing relevant literature; the results showed that the expression of miRNA-222 in prostate cancer tissues was lower than that in prostate hyperplasia tissues (P < 0.05); the expression of miRNA-222, miRNA-1248 and miRNA-3651 in blood samples of prostate cancer patients was lower than that in prostate hyperplasia patients (P < 0.05); the analysis results indicated that the f/t ratio, the relative expression of miRNA-222 and miRNA-1248 were independent influences of prostate cancer (P < 0.05), in which overexpression of miRNA-222 decreased the proliferative, invasive and metastatic abilities of PC3 cells and enhanced the level of apoptosis of cancer cells.
Conclusions
Although there was no significant change in the overall incidence of prostate cancer in this study, significant changes occurred in the incidence of prostate cancer with different characteristics. In addition, the nomogram prediction model of prostate cancer-specific survival rate constructed based on four factors has a high reference value, which helps physicians to correctly assess the patient-specific survival rate and provides a reference basis for patient diagnosis and prognosis evaluation.
Publisher
Research Square Platform LLC
Reference45 articles.
1. Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics;Adamaki M;Pharmacol Ther,2021
2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray F;CA Cancer J Clin,2018
3. WHO. Global health estimates 2020:deaths by cause, age, sex, by Country and by region, 2000–2019[EB/OL]. [2021-02-20]. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death.
4. Cancer Progress and Priorities: Prostate Cancer;Kensler KH;Cancer Epidemiol Biomarkers Prev,2020
5. Trabzonlu L, Kulac I, Zheng Q, et al. Molecular Pathology of High-Grade Prostatic Intraepithelial Neoplasia: Challenges and Opportunities. Cold Spring Harb Perspect Med. 2019 Apr 1;9(4):a030403.